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ABSTRACT 
Background: The chimeric anti-CD20 monoclonal antibody, rituximab, is an 
effective therapeutic agent used for treating patients with B- cell disorders, however 
there is a significant variation in therapy response among patients and relapse is 
common. Furthermore, it is unclear why a class of patients is initially not responding 
and other responding become refractory and later resistant to further treatment.  
Aim: To study the significance of serum anti- rituximab antibodies in the 
patients initially responding to the treatment and became refractory and resistant to 
the treatment.  
Patients and Methods: Serum samples were obtained from forty two patients 
with B- cells disorders after getting their consent, the serum samples were tested for 
the serum anti- rituximab antibodies by enzyme linked immunosorbant assay 
(ELISA). They received rituximab at initial dose of 375 mg/m
2
 and a maintenance 
dose of 500 mg/m
2
. The serum samples were obtained from each patient after 
subsequent doses of treatment.   
Results: The patients’ ages ranged between 20 -80 years. The response rate 50 
days after treatment initiation was 40(95%). During the first year of treatment, the 
complete remission was found in 33(75%) of the patients and 9(21%) of the patients 
developed the non responsiveness to treatment. The serum level of anti- rituximab 
antibodies was detected among 15(36%) of the patients, only 2(22%) of them were 
among the 9 patients who developed the treatment non responsiveness and the other 
13(39%) were among the complete remission patients with no significant difference 
statistically.  
Conclusion: In conclusion, these results indicate that there was no significant 
association between the level of the serum anti rituximab antibodies and the response 
to rituximab treatment. 
Recommendations: We recommend to include a lager sample size of patients 
receiving retuximab for treating diseases other than B cells disorders rheumatoid 
arthritis, SLE  and multiple sclerosis patients.  
Key words: Immunotherapy, Rituximab, B- cell malignancy, Chimeric 
antibodies 
 
Introduction 
Antibody-mediated immunotherapy has gained significant momentum since the first 
FDA-approved monoclonal antibody (mAb) in 1997, namely Rituximab which is a 
chimeric anti-CD20 mAb [1,2]. It is directed against cell surface membrane receptors, 
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CD20, expressed on mature B cells but not on pre-B cells or plasma cells [3]. The 
receptor CD20 is a tetramembrane spanning molecule of molecular weight 33–37 kDa 
and the gene is located on chromosome 11q12-q13.1 
Subsequently, over 20 approved mAbs have been in use clinically for the treatment of 
various cancers and several non-cancer related diseases [4]. Further, the combination 
treatment of mAbs with chemotherapy, immunotherapy, proteaosome inhibitors and 
other inhibitors have resulted in synergistic anti-tumor activity with significant 
objective clinical responses. Despite their successful clinical use, the underlying 
mechanisms of rituximab in vivo activities remain elusive. Further, it is not clear why 
a subset of patients is initially unresponsive and many responding patients become 
refractory and resistant to further treatments; hence, the underlying mechanisms of 
resistance are not known, attempts have been made to develop model systems to 
investigate resistance to mAb therapy with the hope to apply the findings in both the 
generation of new therapeutics as well as their use as new prognostic biomarkers [5]. 
A major limitation of both conventional and targeted therapies is that a subset of 
patients does not initially respond to such therapies and another responding subset 
develops resistance to further treatments. Hence, many malignant cancers exhibit both 
intrinsic and acquired resistance. While the use of rituximab for treatment has been 
successful, however, a subset of patients has an innate resistance. The mechanisms of 
resistance in vivo are not clear. Several mechanisms have been reported including 
inhibition of ADCC by deposition of C3 activating fragments [6], polymorphism of 
the FcγRIIIa on cytotoxic cells [7,8], inhibition of CDC [9], loss of CD20 expression 
on the surface of subclones [10], overexpression of anti-apoptotic gene products (eg 
Bcl2) [11], CD20 mutations [12], shedding of CD20 Rituximab complexes [13] and 
the tumor micro-environment [14]. Development of the antibodies against the 
retuximab by the patient’s immune system due to recurrent doses is not clearly 
reported, since the anti retuximab antibodies are neutralizing and then develop the 
treatment resistance. In the current study, we are aiming at estimating the significance 
of the anti retuximab antibodies in developing therapy resistance in patients with B 
cells disorders.   
 
Patients and methods 
Patients 
         The present study was conducted on patients suffering from B cells disorders, 
who were registered to be treated in the oncology-hematology unit in Azadi Teaching 
Hospital in Duhok city between January 2018 to November 2018. Forty two patients 
with B- cells disorders were recruited in the study, they were diagnosed at the 
oncology- hematology unit as having the B-cell hematologic malignancy, and all of 
the recruited patients have started the rituximab infusion empirical treatment as initial 
dose and then the maintenance dose. Their ages ranged between 20-80 years.   
 
Methods 
       The patients were already diagnosed as B cells disorders patients based on serial 
complete blood count, peripheral blood smear examination, flourescent in situ 
hybridization, and bone marrow examination, at baseline. Sera samples were obtained 
from each patient after subsequent doses of retuximab treatment, the consent has been 
obtained from each patient.  
Al-Kufa University Journal for Biology / VOL.11 / NO.2 / Year: 2019                                     
                       Print ISSN: 2073-8854                Online ISSN: 2311-6544  
 
 
01 
 
 
The presence of anti- retuximab antibodies in the patients’ sera was estimated by the 
ELISA as described by Arnold et al. (2004) [15] with some modifications. Briefly, 
Maxisorp plates (Nunc, Roskilde, Denmark) were coated with 50 ml retuximab (1 
mg/ml) in 0·1 M NaHCO3 pH 9·5.After three washes with wash buffer [20 
mMHEPES, 140 mM NaCl, 5 mM CaCl2, 0·1% (v/v) Tween 20, pH 7·4], wells were 
incubated with 200 ml blocking solution [skimmed milk, 0·1% (v/v) Tween-20, pH 
7·4] overnight at 4°C and washes repeated. Patients’sera, were diluted 1 : 1 in serum 
dilution buffer [40 mMHEPES, 2 MNaCl, 10 mMCaCl2, pH 7·4] and 50 ml per well 
added. Following incubation wells were washed three times with wash buffer. Bound 
anti-retuximab antibodies were detected by horseradish peroxidase-conjugated 
monoclonal anti-human IgG antibodies (Sigma, Poole, UK) in wash buffer. Substrate 
was tetramethyl benzoate (Sigma). All samples were tested in duplicate. The negative 
control wells were used in the plate for comparison. The serum samples were 
considered positive for the anti- retuximab antibodies when color of the reaction 
changed.   
Statistics 
      The association between treatment response and the level of serum anti- 
retuximab antibodies analysed using the χ2 test. 
Results: 
       A total of 42 B-cells malignancy patients were involved in the study, all of them 
were receiving retuximab for different doses and periods, 22(52%) of them were 
males with age range 20-80 years (mean 46 ±4 years) and 20(48%) females with age 
range 25-70 years (mean 42±4 years) as shown in table 1. 
Table 1: Demographic characteristics of the patients 
 
      All of the patients were received rituximab as empirical regimen at initial does of 
375 mg/m2 and followed by maintenance dose of 500mg.m
-2
. The response rate of 50 
days after treatment initiation was 40(95%) and the other 2 patients did not respond to 
the treatment. During the first year of treatment and a media follow up duration of 11 
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months , the complete remission was found in 33(75%) of the patients and 9(21%) of 
the patients developed the non responsiveness to treatment, table 2. 
Table 2: Response rate of B cells malignancy patients to retuximab therapy. 
 
The presence of serum anti- rituximab antibodies was measured by ELISA, the 
antibodies were detected in 15(36%) patients, the others gave negative results for the 
antibody presence, only 2(22%) of them were among the 9 patients who developed 
the treatment non responsiveness and the other 13(39%) were among the complete 
remission patients with no statistical significant difference (p ˂0.001), as shown in 
table 3. 
Table 3: Anti -retximab antibodies in the sera of the patients treated with 
subsequent doses of retuximab detected by ELISA. 
 
Discussion: 
        This study described the possibility of the immune system to develop anti-
rituximab antibodies in B cell disorders patients treated with rituximab which in turn 
establishes a mechanism of treatment resistance. Although rituximab efficacy in 
treating patients of B-cell hematologic malignancies is well studied, some patients are 
refractory to the initial dose of treatment, and others may experience relapse after they 
have responded to the initial dose. In the current study, we found that 21% of the B- 
cell malignancy patients did not respond to the initial dose of treatment and 25% of 
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them experienced relapse after initial response to the treatment. These results are 
comparable with those of a study conducted by Davis et al [16], they found that 30% 
of the patients were partially responding to rituximab treatment. On the other hand, 
our results are inconsistent with those obtained by McLaughlin et al [17]
 
when they 
found that 52% of the patients did not respond to the treatment.  
    The exact mechanisms of the development of resistance to rituximab treatment in 
B- cells amlignancy remain unclear. However, given the reliance of rituximab on 
immune-effectors mechanisms for its antitumor efficacy, it has been hypothesized that 
the host immunologic environment may both play a role [18]. Rituximab  is a 
human/murine chimeric, glycosylated immunoglobulin (Ig) G1-κ mAb containing 
murine light- and heavy-chain variable region sequences, and human kappa and 
human IgG1 constant region sequences, it has specific affinity for the B-lymphocyte 
transmembrane protein, CD20, which is expressed on normal B cells (excluding stem 
cells, pro-B cells, and plasma B cells) and on most malignant B cells [19].  Since the 
rituximab is a chimeric monoclonal antibody, the anitigenicity is proposed, which 
could induce the host immune system and the activation of the immune system may 
interfere with the efficacy of rituximab action and impairment of the treatment 
response.  Based on the composition of the rituximab, patients treated with multiple 
doses of rituximab may develop antibodies against murine variable region sequence, 
named as “human antichimeric antibody” they have the potential to mount 
immunologic reactions when subsequently treated with other antibodies. We found in 
the current study that number of the patients who developed the human antichimeric 
antibody in their sera was 15/42(36%), only 2(22%) of them were among the 
treatment non responsiveness patients, and the other 13(39%) were completely 
remitted patients, and there was no statistical correlation between the resistance to 
treatment and the presence of anti rituximab antibodies in the patients’ sera. Those 
results are in agreement with clinical trials in patients with B-cell malignancies, up to 
2% of patients developed human antichimeric antibody, but no effect of this antibody 
on the efficacy or safety of rituximab has been demonstrated [20]. The non 
effectiveness of the anti-retuximab antibodies developed in by the immune system of 
the patients treated frequently could be due to the immunologic fact that those anti 
bodies are not necessarily targeting the variable region of the paratop of the antibody 
that in turn targets the B-cell CD20 transmembrane protein, so it might not interfere 
with mechanism of action of rituximab.   
Conclusion 
     In conclusion, these results indicate that there was no significant association 
between the presince of the serum anti rituximab antibodies and the response to 
rituximab treatment in patient with B-cell malignancy.  
 
    Conflict of interests Nothing to declare.  
 
References 
 
1. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et 
al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients 
with relapsed low-grade non-Hodgkin’s lymphoma. Blood., (1997). 90:2188–95. 
[PubMed: 9310469]  
Al-Kufa University Journal for Biology / VOL.11 / NO.2 / Year: 2019                                     
                       Print ISSN: 2073-8854                Online ISSN: 2311-6544  
 
 
02 
 
 
 
2. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, et al. 
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: 
results of a phase II trial of rituximab. J Clin Oncol.,(1999). 17:1851–7. [PubMed: 
10561225]  
 
3. Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol 
Clin North Am.,(2012). 26:447–81. [PubMed: 22520975]  
 
4. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its 
potential as a target for mAb therapy. Curr Dir Autoimmun.,(2005). 8:140–74. 
[PubMed: 15564720]   
 
5. Benjamin Bonavida. Postulated Mechanisms of Resistance of B-NHL to Rituximab 
Treatment Regimens: Strategies to Overcome Resistance. Semin Oncol.,(2014). 
41(5): 667–677. doi:10.1053/j.seminoncol.2014.08.006.    
 
6. Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, et al. Bortezomib is 
synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle 
cell lymphoma cells in vitro and in vivo. Leukemia.,(2008). 22:179–85. [PubMed: 
17898787]  
 
7. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. 
Therapeutic activity of humanized anti-CD20 monoclonal antibody and 
polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood.,(2002). 99:754–8. 
[PubMed: 11806974]  
 
8. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms 
independently predict response to rituximab in patients with follicular lymphoma. 
J Clin Oncol., (2003). 21:3940–7. [PubMed: 12975461] 
  
9. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, et al. In vivo targeting 
of human neutralizing antibodies against CD55 and CD59 to lymphoma cells 
increases the antitumor activity of rituximab. Cancer Res.,(2007). 67:10556–63. 
[PubMed: 17975000] 
 
10. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, et al. 
Incidence and nature of CD20-negative relapses following rituximab therapy in 
aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J 
Haematol.,(2002). 119:412–6. [PubMed: 12406079]  
 
11. Jazirehi AR, Vega MI, Bonavida B. Development of Rituximab-Resistant 
Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to 
Chemotherapy. Cancer Res.,(2007). 67:1270–81. [PubMed: 17283164]  
 
12. Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, et al. 
Identification of CD20 C-terminal deletion mutations associated with loss of 
CD20 expression in non-Hodgkin’s lymphoma. Clin Cancer Res.,(2009). 
15:2523–30. [PubMed: 19276251] 
Al-Kufa University Journal for Biology / VOL.11 / NO.2 / Year: 2019                                     
                       Print ISSN: 2073-8854                Online ISSN: 2311-6544  
 
 
03 
 
 
  
13. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving 
reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma 
and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol.,(2006). 
176:2600–9. [PubMed: 16456022] 
  
14. Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic 
lymphocytic leukemia: in vitro models and the significance of CD40-CD154 
interactions. Blood.,(2009). 114:2560–1. [PubMed: 19762501] 
 
15. Arnold JN, Radcliffe CM,Wormald MR et al. The glycosylation of human serum 
IgD and IgE and the accessibility of identified oligomannose structures for 
interaction with mannan-binding lectin.J Immunol.,(2004). 173:6831–40. 
 
16. Banchereau J, Rousset F. Human B lymphocytes: phenotype, proliferation, and 
differentiation. Adv Immunol.,(1992).52:125–262. doi: 10.1016/S0065-
2776(08)60876-7. [PubMed] [CrossRef] [Google Scholar] 
 
17. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 
monoclonal antibody therapy for relapsed indolent lymphoma: half of patients 
respond to a four-dose treatment program. J Clin Oncol.,(1998).16:2825–2833. 
      doi: 10.1200/JCO.1998.16.8.2825. [PubMed] [CrossRef] [Google Scholar] 
 
18. Bonavida B. Postulated mechanisms of resistance of B-cell non-Hodgkin 
lymphoma to rituximab treatment regimens: strategies to overcome 
resistance. Semin Oncol.,(2014).41:667–677. doi: 
10.1053/j.seminoncol.2014.08.006. [PMC free article] [PubMed] 
[CrossRef] [Google Scholar] 
 
19. Mabthera 100 mg concentrate for solution for infusion [summary of product 
characteristics]. Roche Products, Welwyn Garden City., 
(2017). https://www.medicines.org.uk/emc/medicine/2570.  Accessed 18 Sept 
2017. 
 
20. Rituxan
®
 (rituximab) injection, for intravenous use. Genentech, South San 
Francisco. (2016). https://www.gene.com/download/pdf/rituxan_prescribing.pdf. 
Accessed 21 Jun(2017). 
 
 
 
